SANTA CLARA, Calif.--(BUSINESS WIRE)--NewCardio, Inc. (OTCBB: NWCI), a cardiac diagnostic and services company, today announced the launch of a third external clinical validation study, to be completed simultaneously with the Company’s ongoing commercialization effort for its lead product, QTinno™.
